This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Inclusion Criteria:

• Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
• Clinically localized (no evidence on clinical or imaging studies of advanced disease).
• No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
• Sufficient amount of tissue remains from biopsy to perform genomic testing.

Exclusion Criteria:

• Patients with a known history of hypogonadism

Recently diagnosed treatment-naïve patients with early stage localized prostate cancer